With its worldwide impact and mounting death toll, the 2017-2018 influenza season shows that the viral disease isn’t just a fever and the sniffles, but rather a dangerous disease that can spread rapidly between people. That’s why a leading healthcare technology company is pushing forward with trials that can help doctors and medical staff easily identify the disease early in the process through a simple breath test.
At HIMSS18, Philips plans to announce several new additions to its line of connected care products. A new management system called FocusPoint will help give hospitals more visibility into the performance of their patient monitoring technology.
The new Cios Select offers many features designed specifically for intraoperative imaging in orthopaedics, trauma surgery, urology, pain management, and peripheral vascular surgery. Credit: Siemens Healthineers.
A new gene therapy to treat a debilitating eye disorder is one step closer to regulatory approval in Europe. Gene therapy company MeiraGTx said the European Medicines Agency granted Priority Medicines (PRIME) designation to its candidate A002 for treatment of achromatopsia.
Qualcomm Life announced an exclusive licensing agreement with AlertWatch, creator of an FDA-cleared intelligence care software that assists in the care of patients in the operating room. The deal will give Qualcomm Life the exclusive rights to sell AlertWatch, which the company plans to showcase at HIMSS 2018.
The Arab Health Exhibition 2018 was successfully held at the Dubai International Convention & Exhibition Centre from January 29th to February 1st, 2018. Ddu, the leading global pharmaceutical & medical device B2B online platform, attended the exhibition along with three priority members, taking home valuable resources.
Generation Bio said it closed a $100 million series B financing to advance to the clinic its first two therapeutics candidates using its GeneWave platform to develop a new class of genetic medicines with drug-like qualities.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.